CWA Asset Management Group LLC Has $665,000 Stock Position in Innoviva, Inc. (NASDAQ:INVA)

CWA Asset Management Group LLC lifted its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 29.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,355 shares of the biotechnology company’s stock after buying an additional 8,645 shares during the period. CWA Asset Management Group LLC’s holdings in Innoviva were worth $665,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. US Bancorp DE boosted its position in Innoviva by 24.5% during the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock worth $56,000 after buying an additional 566 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Innoviva by 18.5% during the third quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 643 shares during the period. FMR LLC lifted its holdings in shares of Innoviva by 8.2% during the third quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 771 shares during the period. Walleye Capital LLC bought a new stake in shares of Innoviva in the third quarter worth $214,000. Finally, World Investment Advisors LLC acquired a new stake in Innoviva in the third quarter valued at $217,000. 99.12% of the stock is currently owned by institutional investors.

Innoviva Stock Performance

Shares of INVA stock opened at $17.31 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. Innoviva, Inc. has a one year low of $14.32 and a one year high of $21.28. The business’s 50 day simple moving average is $18.73 and its 200 day simple moving average is $18.65. The stock has a market capitalization of $1.08 billion, a PE ratio of 25.09 and a beta of 0.54.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The firm had revenue of $89.51 million during the quarter. As a group, research analysts forecast that Innoviva, Inc. will post 0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Innoviva from a “buy” rating to a “hold” rating in a report on Tuesday, December 31st.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.